New clinical trials in CUP and a novel paradigm in cancer classification

被引：0
|
作者：
Rassy, Elie [1 ,2 ]
Andre, Fabrice [1 ,3 ]
机构：
[1] Univ Paris Saclay, Dept Med Oncol, Gustave Roussy, Villejuif, France
[2] Univ Paris Saclay, CESP, INSERM, U1018, Villejuif, France
[3] Univ Paris Saclay, Gustave Roussy, INSERM, U981, Villejuif, France
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2024年 / 21卷 / 12期
关键词：
D O I：
10.1038/s41571-024-00942-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Precision oncology has reached a milestone as data from two trials in which molecular profiling guided both site-specific and tumour-agnostic therapies indicate improved survival outcomes in patients with cancer of unknown primary. These findings can also be extrapolated and support the use of tissue-agnostic approaches in general, and also suggest that the tissue of origin might have a role in the agnostic classification of cancers and their response to treatment.
引用
收藏
页码：833 / 834
页数：2
相关论文
共 50 条
12345